LUNGNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Pulmonx Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$1.75−0.03 (-1.69%)
Close on Oct 19, 2026
- Market cap
- $74.32M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.23 (+15.13%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Pulmonx Corp saw revenue fall 3.4% to $87.44M over the twelve months to Jun 30, 2026. Free cash flow was -$30.67M.
Revenue
$87.44M
-3.4% vs. a year earlier
Operating income
-$46.31M
TTM Q2 2026
Free cash flow
-$30.67M
TTM Q2 2026
EPS, diluted
-$1.16
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $74.32M
- P/E ratio
- –
- Price to sales
- 0.85
- Price to book
- 1.90
- Dividend yield
- –
- Free cash flow yield
- -41.27%
Fundamentals
- Revenue
- $87.44M
- Net income
- -$48.12M
- EPS, diluted
- -$1.16
- Free cash flow
- -$30.67M
- Book value per share
- $0.92
- Diluted shares
- 42M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$87.44M-3.4% YoY
Gross profit
$67.38M+1.8% YoY
Operating income
-$46.31M
Net income
-$48.12M
EPS, diluted
-$1.16
Free cash flow
-$30.67M
Reported periodTrailing twelve months